 As a director of T-cell Informa program, my goal and the role is to develop a comprehensive research program. T-cell Informa is quite rare. They're much less studied and the prognosis of T-cell Informa is much worse and the standard of care is very inadequate. I wouldn't say that there is a dramatic breakthrough but we learned a lot about mechanics, cellular mechanics of T-cell Informa, how they develop differences and based on that there's a lot of novel therapeutics being developed based on our knowledge of intracellular mechanism. So those drugs will block particular pathways which this Limfoma cell is addicted to and so the Limfoma cell will die. I think the most exciting area in diffuse large B-cell Limfoma is immunotherapy. What I'm talking about is cart-19 cells that's basically patient-owned telemphaside genetically modified so they attack the Limfoma cells. With data across the board showing 40% cure in a situation when they were basically 0% cure. Coming in mass is bite antibody so it's called bite means bispecific T-cell Engager. It's basically an interesting modality when it's an antibody which has two arms. One grabs the Limfoma cell and another one grabs the telemphaside which is supposed to fight it and they're also very very interesting results with we cannot say cure but very promising. In Hatchkin Limfoma field there are two major drugs which I would say completely change the outcomes of Hatchkin Limfoma and relapse settings. One is older drug it's a drug antibody conjugate of CD30 with very potent toxin called MMAE and the drug is called Brintuximabvidotin and a second class of the drugs belong to what we call PD1 inhibitors and the two drugs approved on Hatchkin Limfoma nivolumab and pembrolizumab and a lot of studies ongoing combining these drugs together in relapse setting showing quite impressive results as well as moving these two drugs in frontline therapies with several ongoing multi-institutional protocols happening and we will have answers within next I'd say five years which may change how we treat Hatchkin Limfoma.